These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30907010)

  • 41. Investigation of factors associated with allergic transfusion reaction due to platelet transfusion and the efficacy of platelets resuspended in BRS-A in adult patients.
    Yamanaka M; Yanagisawa R; Kojima S; Nakazawa H; Shimodaira S
    Transfusion; 2019 Nov; 59(11):3405-3412. PubMed ID: 31532542
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduction in adverse reactions to platelets by the removal of plasma supernatant and resuspension in a new additive solution (M-sol).
    Azuma H; Hirayama J; Akino M; Miura R; Kiyama Y; Imai K; Kasai M; Koizumi K; Kakinoki Y; Makiguchi Y; Kubo K; Atsuta Y; Fujihara M; Homma C; Yamamoto S; Kato T; Ikeda H
    Transfusion; 2009 Feb; 49(2):214-8. PubMed ID: 18798806
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Apheresis platelets are more frequently associated with adverse reactions than pooled platelets both in recipients and in donors: a study from French hemovigilance data.
    Daurat A; Roger C; Gris J; Daurat G; Feissel M; Le Manach Y; Lefrant J; Muller L
    Transfusion; 2016 Jun; 56(6):1295-303. PubMed ID: 26814984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Residual risk and retrospective analysis of transfusion-transmitted bacterial infection reported by the French National Hemovigilance Network from 2000 to 2008.
    Lafeuillade B; Eb F; Ounnoughene N; Petermann R; Daurat G; Huyghe G; Vo Mai MP; Caldani C; Rebibo D; Weinbreck P
    Transfusion; 2015 Mar; 55(3):636-46. PubMed ID: 25257344
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution.
    Ignatova AA; Karpova OV; Trakhtman PE; Rumiantsev SA; Panteleev MA
    Vox Sang; 2016 Apr; 110(3):244-52. PubMed ID: 26646605
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Study of acute transfusion reactions in a teaching hospital of Sikkim: A hemovigilance initiative.
    Sharma DK; Datta S; Gupta A
    Indian J Pharmacol; 2015; 47(4):370-4. PubMed ID: 26285707
    [TBL] [Abstract][Full Text] [Related]  

  • 47. In vitro evaluation of pooled buffy coat platelets treated with photochemical pathogen inactivation using amotosalen.
    Cazenave JP; Aleil B; Wiesel ML; Laforêt M; Isola H
    Vox Sang; 2004 Apr; 86(3):201-2. PubMed ID: 15078258
    [No Abstract]   [Full Text] [Related]  

  • 48. A Comparison of Transfusion-Related Adverse Reactions Among Apheresis Platelets, Whole Blood-Derived Platelets, and Platelets Subjected to Pathogen Reduction Technology as Reported to the National Healthcare Safety Network Hemovigilance Module.
    Mowla SJ; Kracalik IT; Sapiano MRP; O'Hearn L; Andrzejewski C; Basavaraju SV
    Transfus Med Rev; 2021 Apr; 35(2):78-84. PubMed ID: 33934903
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Differential protein expression of blood platelet components associated with adverse transfusion reactions.
    Aloui C; Barlier C; Claverol S; Fagan J; Awounou D; Tavernier E; Guyotat D; Hamzeh-Cognasse H; Cognasse F; Garraud O; Laradi S
    J Proteomics; 2019 Mar; 194():25-36. PubMed ID: 30590131
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Preventing adverse reactions in pediatric transfusions using washed platelet concentrate.
    Yanagisawa R
    Pediatr Int; 2021 Apr; 63(4):391-403. PubMed ID: 33290634
    [TBL] [Abstract][Full Text] [Related]  

  • 51. DAMPS and complement activation in platelet concentrates that induce adverse reactions in patients.
    de Wit YES; Hamzeh-Cognasse H; Cognasse F; Ten Brinke A; Zeerleder SS
    Transfusion; 2022 Sep; 62(9):1721-1726. PubMed ID: 35950480
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A multi-centre study of therapeutic efficacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion.
    Lozano M; Knutson F; Tardivel R; Cid J; Maymó RM; Löf H; Roddie H; Pelly J; Docherty A; Sherman C; Lin L; Propst M; Corash L; Prowse C
    Br J Haematol; 2011 May; 153(3):393-401. PubMed ID: 21418180
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In-vivo evaluation of random donor platelet concentrates from pooled buffy coats.
    Klüter H; Dörges L; Maass E; Wagner T; Bartels H; Kirchner H
    Ann Hematol; 1996 Aug; 73(2):85-9. PubMed ID: 8774617
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Transfusion-related adverse reactions reported to the National Healthcare Safety Network Hemovigilance Module, United States, 2010 to 2012.
    Harvey AR; Basavaraju SV; Chung KW; Kuehnert MJ
    Transfusion; 2015 Apr; 55(4):709-18. PubMed ID: 25371300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Analysis of transfusion incident reports filed at 15 blood transfusion centers and health facilities during 17 months. Groupe Receveurs de laSFTS].
    Waller C; Vicariot M; Gunzberger H
    Transfus Clin Biol; 1997 Dec; 4(6):541-8. PubMed ID: 9527419
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Feasibility study for Intercept platelets].
    Bardiaux L; Vauzou S; Olivier B; Mathieu-Daude D; Durand E; Dite C; Roubinet F
    Transfus Clin Biol; 2016 Nov; 23(4):212-216. PubMed ID: 27644172
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antioxidant power as a quality control marker for completeness of amotosalen and ultraviolet A photochemical treatments in platelet concentrates and plasma units.
    Abonnenc M; Crettaz D; Tacchini P; Di Vincenzo L; Sonego G; Prudent M; Tissot JD; Lion N
    Transfusion; 2016 Jul; 56(7):1819-27. PubMed ID: 27184608
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Determination
    Thuku NW; Shikuku K; Mbugua A
    Pan Afr Med J; 2017; 27():226. PubMed ID: 28979628
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Single-donor (apheresis) platelets and pooled whole-blood-derived platelets--significance and assessment of both blood products].
    Hitzler WE
    Clin Lab; 2014; 60(4):S1-39. PubMed ID: 24779310
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Generation of procoagulant collagen- and thrombin-activated platelets in platelet concentrates derived from buffy coat: the role of processing, pathogen inactivation, and storage.
    Bertaggia Calderara D; Crettaz D; Aliotta A; Barelli S; Tissot JD; Prudent M; Alberio L
    Transfusion; 2018 Oct; 58(10):2395-2406. PubMed ID: 30229925
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.